Fujirebio
Biotechnology ResearchTokio, Japan501-1000 Employees
Fujirebio is a biotechnology research company that specializes in in vitro diagnostics (IVD) and the development of diagnostic content to support tests across oncology, infectious diseases, and neurological disorders. Founded in Tokyo in 1950, Fujirebio has developed biomarkers and diagnostic technologies and collaborates with leading diagnostic companies across multiple platforms to deliver global solutions. The company operates an open business model that reinvests more than 15% of base revenue into research and development, validates new content on its Lumipulse platform, and shares proven solutions globally through contract development and manufacturing organization CDMO services. Fujirebio has a notable focus on neurological diagnostics, including the FDA-cleared Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test, and strengthened its pipeline with the 2022 acquisition of ADx NeuroSciences. The company is a consolidated subsidiary of H.U. Group Holdings, Inc., headquartered in Tokyo, Japan, with a workforce of 501-1000 employees, and has pursued 2025 strategic activities such as a collaboration with Stanford Medicine and the acquisition of Plasma Services Group.
1-888-653-2347 
support@leadiq.com 
